NcodiN | $18,456,480 | (Nov 21, 2025)
Voio | $8,600,000 | (Nov 21, 2025)
Stuut | $29,500,000 | (Nov 21, 2025)
Certified by Founder
Lodge
GC Therapeutics
start up
United States
- Cambridge, MA
- 24/09/2024
- Series A
- $65,000,000
GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases.
The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.
- Industry Biotechnology Research
- Website https://www.gc-tx.com/
- LinkedIn https://www.linkedin.com/company/gctx/
Made Card | $8,000,000 | (Nov 21, 2025)
Poly(US) | $8,000,000 | (Nov 21, 2025)
Runlayer | $11,000,000 | (Nov 21, 2025)
AI Proteins | $41,500,000 | (Nov 21, 2025)
Automat | $15,500,000 | (Nov 21, 2025)
EQORE | $1,700,000 | (Nov 21, 2025)
Poppy Flowers | $2,700,000 | (Nov 21, 2025)
WellBeam Inc | $10,000,000 | (Nov 21, 2025)
Revenium | $13,500,000 | (Nov 21, 2025)